On 23rd April, Lukang Pharma's self-developed Class II new veterinary drug for pets, Firocoxib and its chewable tablets were approved by the Ministry of Agriculture and issued a new drug certificate, making Lukang Pharma the first enterprise in China to approve the registration of this product.

Spring begins in March, and everything blooms. In order to deeply implementing the spirit of 20th CPC National Congress and new development concept, build an happiness enterprise to lead and inspire female staff play the role of "Half the Sky", LUKANG PHARMA has organized more than 40 labour unions to carry out a series of activities in themes of celebrating the Women's Day.

On Nov. 17-19, 2023 China Pharmaceutical Industry Development Conference was held in Beijing. During the 40th National Pharmaceutical Industry Information Conference & 2022 Top 100 China Pharmaceutical Industry Forum, the highly anticipated "2022 China Pharmaceutical Industry Top 100 List" was published, Lukang pharma entered the China Pharmaceutical Industry Top 100 List again.

Recently, Lukang pharma successfully passed the re-certification of the National Enterprise Technology Center with "excellent" results.

The application for consistency evaluation of Nifedipine Sustained-release Tablets (I) (10mg) of Lukang Saite Company was approved by NMPA and was officially approved on August 31.

The company's Tofacitinb Citrate Tables (5mg) was obtained drug registration certificate (No.: 2023S01222) approved by NMPA on Aug. 01, which was the first anti-rheumatoid arthritis product got Marketing Authorization

On 23rd April, Lukang Pharma's self-developed Class II new veterinary drug for pets, Firocoxib and its chewable tablets were approved by the Ministry of Agriculture and issued a new drug certificate, making Lukang Pharma the first enterprise in China to approve the registration of this product.

On 23rd April, Lukang Pharma's self-developed Class II new veterinary drug for pets, Firocoxib and its chewable tablets were approved by the Ministry of Agriculture and issued a new drug certificate, making Lukang Pharma the first enterprise in China to approve the registration of this product.

Spring begins in March, and everything blooms. In order to deeply implementing the spirit of 20th CPC National Congress and new development concept, build an happiness enterprise to lead and inspire female staff play the role of "Half the Sky", LUKANG PHARMA has organized more than 40 labour unions to carry out a series of activities in themes of celebrating the Women's Day.

On Nov. 17-19, 2023 China Pharmaceutical Industry Development Conference was held in Beijing. During the 40th National Pharmaceutical Industry Information Conference & 2022 Top 100 China Pharmaceutical Industry Forum, the highly anticipated "2022 China Pharmaceutical Industry Top 100 List" was published, Lukang pharma entered the China Pharmaceutical Industry Top 100 List again.

Recently, Lukang pharma successfully passed the re-certification of the National Enterprise Technology Center with "excellent" results.

The application for consistency evaluation of Nifedipine Sustained-release Tablets (I) (10mg) of Lukang Saite Company was approved by NMPA and was officially approved on August 31.

The company's Tofacitinb Citrate Tables (5mg) was obtained drug registration certificate (No.: 2023S01222) approved by NMPA on Aug. 01, which was the first anti-rheumatoid arthritis product got Marketing Authorization